Astellas Pharma News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

08.06.23	Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430 (PR Newswire)
25.05.23	Astellas Highlights Continued Delivery of Strong Cancer Portfolio and Pipeline at 2023 ASCO Annual Meeting (PR Newswire)
25.05.23	Astellas Announces Commitments to 3rd Phase of GHIT Fund Replenishment (PR Newswire)
16.05.23	Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field (PR Newswire)
16.05.23	Astellas Pharma Enters Into Joint Research Agreement With Sony (RTTNews)
16.05.23	Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field (PR Newswire)
12.05.23	Astellas' VEOZAH™ (fezolinetant) Approved by U.S. FDA for Treatment of Vasomotor Symptoms Due to Menopause (PR Newswire)
01.05.23	Astellas Pharma To Acquire Iveric Bio In $5.9 Bln Deal (RTTNews)
01.05.23	Astellas Enters into Definitive Agreement to Acquire Iveric Bio (PR Newswire)
29.04.23	XTANDI® (enzalutamide) plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide (PR Newswire)
15.04.23	Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet (PR Newswire)
12.04.23	CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells (PR Newswire)
04.04.23	Seagen: FDA Grants Accelerated Approval For Padcev Combination To Treat Metastatic Urothelial Cancer (RTTNews)
03.04.23	FDA Grants Accelerated Approval for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (PR Newswire)
29.03.23	Astellas, Roche To Develop Integrated Diabetes Self-management Solution With BlueStar (RTTNews)
29.03.23	Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar® (PR Newswire)
23.03.23	Pfizer And Astellas Say Phase 3 EMBARK Study Of XTANDI To Treat Prostate Cancer Meets Primary Goal (RTTNews)
21.03.23	Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series (PR Newswire)
17.03.23	Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer (PR Newswire)
14.03.23	Astellas : Phase 3 Study Of Xtandi In Metastatic Hormone-sensitive Prostate Cancer Meets Main Goal (RTTNews)
14.03.23	Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet (PR Newswire)
14.03.23	Astellas Announces Phase 3 China ARCHES Study of XTANDI® Meets Primary Endpoint (PR Newswire)
10.03.23	Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic U... (PR Newswire)
09.03.23	Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib (PR Newswire)
22.02.23	Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease (PR Newswire)
20.02.23	Astellas Provides Update on Fezolinetant New Drug Application in U.S. (PR Newswire)
09.02.23	Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050 (PR Newswire)
06.02.23	Astellas Pharma Board Approves Changes Of Management Structure (RTTNews)
06.02.23	Astellas Announces Change of President and CEO and Management Structure (PR Newswire)
05.02.23	Ausblick: Astellas Pharma stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
24.01.23	Sandoz To Acquire Antifungal Agent Mycamine From Astellas Pharma (RTTNews)
24.01.23	Astellas Transfers MYCAMINE® Product Worldwide (PR Newswire)
22.01.23	Erste Schätzungen: Astellas Pharma stellt das Zahlenwerk zum vergangenen Quartal vor (finanzen.net)
20.01.23	Astellas Pharma : FDA Lifts Clinical Hold On Trial Of AT845 In Late-Onset Pompe Disease (RTTNews)
20.01.23	Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease (PR Newswire)
19.01.23	Astellas to Present Positive Findings from Phase 3 SPOTLIGHT Trial of Zolbetuximab during 2023 ASCO GI Cancers Symposium (PR Newswire)
19.01.23	Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions (PR Newswire)
09.01.23	Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease (PR Newswire)
22.12.22	Astellas, 3 Other Companies Collaborate To Reduce Environmental Burden In Field Of Pharma Packaging (RTTNews)
22.12.22	Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging (PR Newswire)
20.12.22	Astellas: PADCEV, KEYTRUDA Granted Priority Review In Treatment Of Metastatic Urothelial Cancer (RTTNews)
20.12.22	Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment ... (PR Newswire)
16.12.22	Astellas Announces Positive Results From Phase 3 Trial Of Zolbetuximab Combination In Gastric Cancer (RTTNews)
16.12.22	Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and... (PR Newswire)
14.12.22	Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio (PR Newswire)
17.11.22	Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroe... (PR Newswire)
30.10.22	Ausblick: Astellas Pharma legt Zahlen zum jüngsten Quartal vor (finanzen.net)
25.10.22	Astellas Pharma To Support Development Of Taysha's AAV-based Gene Therapy Programs (RTTNews)
25.10.22	Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs (PR Newswire)
16.10.22	Erste Schätzungen: Astellas Pharma verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.55	2.53 %	K V
Lonza Grp	528.60	1.38 %	K V
Part Grp Hldg	1’273.50	0.79 %	K V
Logitech Intl	71.58	0.79 %	K V
UBS Group	28.52	0.78 %	K V
Roche Hldg G	253.70	-0.24 %	K V
Swisscom	507.50	-0.39 %	K V
Zurich Insur Gr	550.40	-0.47 %	K V
Swiss Life Hldg	729.80	-0.52 %	K V
Novartis	92.79	-0.95 %	K V

Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Sh

Aktien Top/Flop

Meistgelesene Nachrichten